

Genomic Landscape of Myelodysplastic Syndromes

Guest Editor:

Prof. Dr. Nicolas Bonadies

Hemato-Oncology, Hirslanden
Bern, Bern, Switzerland

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,


The genomic landscape of MDS is complex and heterogeneous, involving a multitude of genetic and epigenetic alterations that drive disease pathogenesis and progression. Understanding these molecular mechanisms is essential for improving risk stratification, developing targeted therapies, and ultimately improving outcomes for patients with MDS.

We encourage researchers to submit articles in this Special Issue dedicated to the diagnostic, prognostic, predictive implications as well as minimal-residual disease monitoring of genetic and epigenetic alterations in myelodysplastic syndromes. These may include following aspects:

- Cytogenetic Abnormalities
- Somatic Mutations
- Clonal Evolution
- Epigenetic Alterations
- Clonal Hematopoiesis of Indeterminate Potential
- Therapeutic Implications

We look forward to receiving your contributions to further elucidate the genomic landscape of MDS and ultimately offer the potential for better outcomes for patients with this complex disorder.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)